WO2008034122A3 - Hindered ester-based biodegradable linkers for oligonucleotide delivery - Google Patents

Hindered ester-based biodegradable linkers for oligonucleotide delivery Download PDF

Info

Publication number
WO2008034122A3
WO2008034122A3 PCT/US2007/078597 US2007078597W WO2008034122A3 WO 2008034122 A3 WO2008034122 A3 WO 2008034122A3 US 2007078597 W US2007078597 W US 2007078597W WO 2008034122 A3 WO2008034122 A3 WO 2008034122A3
Authority
WO
WIPO (PCT)
Prior art keywords
based biodegradable
hindered ester
oligonucleotide delivery
biodegradable linkers
linkers
Prior art date
Application number
PCT/US2007/078597
Other languages
French (fr)
Other versions
WO2008034122A2 (en
Inventor
Hong Zhao
Original Assignee
Enzon Pharmaceuticals Inc
Hong Zhao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzon Pharmaceuticals Inc, Hong Zhao filed Critical Enzon Pharmaceuticals Inc
Priority to EP07842576A priority Critical patent/EP2063709A2/en
Priority to AU2007296054A priority patent/AU2007296054B2/en
Priority to MX2009002859A priority patent/MX2009002859A/en
Priority to CA002662978A priority patent/CA2662978A1/en
Priority to JP2009528517A priority patent/JP2010503707A/en
Publication of WO2008034122A2 publication Critical patent/WO2008034122A2/en
Publication of WO2008034122A3 publication Critical patent/WO2008034122A3/en
Priority to IL197516A priority patent/IL197516A0/en
Priority to US12/402,743 priority patent/US8110559B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
    • A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Biomedical Technology (AREA)
  • Agronomy & Crop Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pest Control & Pesticides (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

The invention provides hindered ester-based biodegradable linkers for the delivery of oligonucleotides in vivo, as well as method of making and using the same.
PCT/US2007/078597 2006-09-15 2007-09-15 Hindered ester-based biodegradable linkers for oligonucleotide delivery WO2008034122A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP07842576A EP2063709A2 (en) 2006-09-15 2007-09-15 Hindered ester-based biodegradable linkers for oligonucleotide delivery
AU2007296054A AU2007296054B2 (en) 2006-09-15 2007-09-15 Hindered ester-based biodegradable linkers for oligonucleotide delivery
MX2009002859A MX2009002859A (en) 2006-09-15 2007-09-15 Hindered ester-based biodegradable linkers for oligonucleotide delivery.
CA002662978A CA2662978A1 (en) 2006-09-15 2007-09-15 Hindered ester-based biodegradable linkers for oligonucleotide delivery
JP2009528517A JP2010503707A (en) 2006-09-15 2007-09-15 Hindered ester biodegradable linkers for oligonucleotide delivery
IL197516A IL197516A0 (en) 2006-09-15 2009-03-10 Ester-based polymeric delivery systems
US12/402,743 US8110559B2 (en) 2006-09-15 2009-03-12 Hindered ester-based biodegradable linkers for oligonucleotide delivery

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84502806P 2006-09-15 2006-09-15
US60/845,028 2006-09-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/402,743 Continuation US8110559B2 (en) 2006-09-15 2009-03-12 Hindered ester-based biodegradable linkers for oligonucleotide delivery

Publications (2)

Publication Number Publication Date
WO2008034122A2 WO2008034122A2 (en) 2008-03-20
WO2008034122A3 true WO2008034122A3 (en) 2008-10-30

Family

ID=39184642

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/078597 WO2008034122A2 (en) 2006-09-15 2007-09-15 Hindered ester-based biodegradable linkers for oligonucleotide delivery

Country Status (9)

Country Link
EP (1) EP2063709A2 (en)
JP (1) JP2010503707A (en)
KR (1) KR20090055623A (en)
CN (1) CN101534643A (en)
AU (1) AU2007296054B2 (en)
CA (1) CA2662978A1 (en)
IL (1) IL197516A0 (en)
MX (1) MX2009002859A (en)
WO (1) WO2008034122A2 (en)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102851291B (en) 2006-04-03 2016-03-09 斯特拉有限责任公司 Comprise the pharmaceutical composition of anti-miRNA antisense oligonucleotides
KR101407707B1 (en) 2006-04-03 2014-06-19 산타리스 팔마 에이/에스 Pharmaceuical composition comprising anti-mirna antisense oligonucleotides
CA2662962A1 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Polyalkylene oxides having hindered ester-based biodegradable linkers
TW200836762A (en) * 2006-11-27 2008-09-16 Enzon Pharmaceuticals Inc Polymeric short interfering RNA conjugates
WO2008113832A2 (en) 2007-03-22 2008-09-25 Santaris Pharma A/S SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA
EP2126079A1 (en) 2007-03-22 2009-12-02 Santaris Pharma A/S Rna antagonist compounds for the inhibition of apo-b100 expression
NZ581200A (en) 2007-05-01 2012-04-27 Santaris Pharma As Rna antagonist compounds for the modulation of beta-catenin
KR20100024410A (en) 2007-05-11 2010-03-05 엔즌 파마슈티칼스, 인코포레이티드 Rna antagonist compounds for the modulation of her3
MX2010003109A (en) 2007-09-24 2010-04-01 Noxxon Pharma Ag C5a BINDING NUCLEIC ACIDS.
CN101821391B (en) 2007-10-04 2016-04-27 桑塔里斯制药公司 Micromirs
MX2010005703A (en) 2007-11-26 2010-06-11 Enzon Pharmaceuticals Inc Lna antagonists targeting the androgen receptor.
US8450290B2 (en) 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
MX2010006039A (en) 2007-12-03 2010-06-23 Enzon Pharmaceuticals Inc Rna antagonist compounds for the modulation of pik3ca expression.
US8404659B2 (en) 2008-03-07 2013-03-26 Santaris Pharma A/S Pharmaceutical compositions for treatment of MicroRNA related diseases
WO2010012667A1 (en) 2008-08-01 2010-02-04 Santaris Pharma A/S Micro-rna mediated modulation of colony stimulating factors
KR101660059B1 (en) * 2008-08-22 2016-09-26 박스알타 인코퍼레이티드 Polymeric benzyl carbonate-derivatives
WO2010108657A2 (en) 2009-03-23 2010-09-30 Noxxon Pharma Ag C5a binding nucleic acids and the use thereof
EP2421970B1 (en) 2009-04-24 2016-09-07 Roche Innovation Center Copenhagen A/S Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
BR112012000214A2 (en) 2009-06-12 2018-06-19 Santaris Pharma As potent antisense compounds anti - apob
EP2456870A1 (en) 2009-07-21 2012-05-30 Santaris Pharma A/S Antisense oligomers targeting pcsk9
SI2459220T1 (en) 2009-07-31 2020-12-31 Ascendis Pharma A/S Biodegradable polyethylene glycol based water-insoluble hydrogels
UA108475C2 (en) 2009-07-31 2015-05-12 Санофі-Авентіс Дойчланд Гмбх Long-acting insulin composition
JP5738291B2 (en) 2009-07-31 2015-06-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Prodrugs containing insulin linker conjugates
WO2011048125A1 (en) 2009-10-20 2011-04-28 Santaris Pharma A/S Oral delivery of therapeutically effective lna oligonucleotides
WO2011054811A1 (en) 2009-11-03 2011-05-12 Santaris Pharma A/S Rna antagonists targeting hsp27 combination therapy
WO2011131371A1 (en) 2010-04-21 2011-10-27 Noxxon Pharma Ag Lipid binding nucleic acids
WO2012007477A1 (en) 2010-07-12 2012-01-19 Santaris Pharma A/S Anti hcv oligomers
WO2012025251A1 (en) 2010-08-27 2012-03-01 Noxxon Pharma Ag Nucleic acids for treatment of chronic complications of diabetes
SG188220A1 (en) 2010-09-09 2013-04-30 Noxxon Pharma Ag Sdf-1 binding nucleic acids and the use thereof in cancer treatment
WO2012034942A1 (en) 2010-09-13 2012-03-22 Santaris Pharma A/S Compounds for the modulation of aurora kinase b expression
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
JP2014503187A (en) 2010-10-29 2014-02-13 ノクソン ファーマ エージー Use of hepcidin-binding nucleic acids to remove hepcidin from the body
WO2012065051A1 (en) 2010-11-12 2012-05-18 Enzon Pharmaceuticals, Inc. Compositions and methods for treating androgen receptor dependent disorders including cancers
WO2012066092A1 (en) 2010-11-19 2012-05-24 Santaris Pharma A/S Compounds for the modulation of aurora kinase a expression
WO2012066093A1 (en) 2010-11-19 2012-05-24 Santaris Pharma A/S Compounds for the modulation of pdz-binding kinase (pbk) expression
EP2663640B1 (en) 2011-01-10 2020-11-04 APTARION biotech AG Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same
WO2012110457A2 (en) 2011-02-14 2012-08-23 Santaris Pharma A/S Compounds for the modulation of osteopontin expression
WO2012143427A1 (en) 2011-04-19 2012-10-26 Santaris Pharma A/S Anti polyomavirus compounds
US20140127159A1 (en) 2011-06-23 2014-05-08 Stella Aps HCV Combination Therapy
US20140113958A1 (en) 2011-06-30 2014-04-24 Stella Aps HCV Combination Therapy
EP2726611A1 (en) 2011-06-30 2014-05-07 Stella ApS Hcv combination therapy
ES2535654T3 (en) * 2011-10-13 2015-05-13 Association Institut De Myologie Tricyclo phosphorothioate DNA
JP2014533098A (en) 2011-10-21 2014-12-11 ノクソン・ファルマ・アクチエンゲゼルシャフト Glucagon binding nucleic acid
AU2012334214A1 (en) 2011-11-07 2014-05-22 Roche Innovation Center Copenhagen A/S Prognostic method for checking efficacy of micro RNA-122 inhibitors in HCV+ patients
CA2855241A1 (en) 2011-11-11 2013-05-16 Santaris Pharma A/S Compounds for the modulation of smn2 splicing
US9518265B2 (en) 2012-01-10 2016-12-13 Noxxon Pharma Ag C5a binding nucleic acids
AU2013209130A1 (en) 2012-01-10 2014-07-10 Noxxon Pharma Ag Nucleic acids specifically binding CGRP
ES2965777T3 (en) 2012-05-16 2024-04-16 Aptarion Biotech Ag Enzymatic synthesis of L-nucleic acids
EP2920304B1 (en) 2012-11-15 2019-03-06 Roche Innovation Center Copenhagen A/S Oligonucleotide conjugates
RU2015120645A (en) 2012-11-26 2017-01-10 Рош Инновейшен Сентер Копенгаген А/С COMPOSITIONS AND METHODS OF MODULATION OF EXPRESSION OF RECEPTOR OF FACTOR OF GROWTH FIBROBLAST 3 TYPE (FGFR3)
SG10201908122XA (en) 2013-06-27 2019-10-30 Roche Innovation Ct Copenhagen As Antisense oligomers and conjugates targeting pcsk9
US20170233737A1 (en) 2013-11-04 2017-08-17 Noxxon Pharma Ag Means and Methods for the Treatment of Nephropathy
GB201408623D0 (en) 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
GB201414098D0 (en) * 2014-08-08 2014-09-24 Illumina Cambridge Ltd Modified nucleotide linkers
WO2016096938A1 (en) 2014-12-16 2016-06-23 Roche Innovation Center Copenhagen A/S Chiral toxicity screening method
NZ743488A (en) 2016-01-08 2023-02-24 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with low initial npr-b activity
MX2018008061A (en) 2016-01-08 2018-08-23 Ascendis Pharma Growth Disorders As Cnp prodrugs with large carrier moieties.
AU2017205273C1 (en) 2016-01-08 2022-12-01 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with reduced side-effects
CA3008015A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release c-type natriuretic peptide agonists with increased neutral endopeptidase stability
RS63793B1 (en) 2016-01-08 2022-12-30 Ascendis Pharma Growth Disorders As Cnp prodrugs with carrier attachment at the ring moiety
IL259829B2 (en) 2016-01-08 2023-03-01 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with low npr-c binding
RU2747316C2 (en) 2016-03-01 2021-05-04 Асцендис Фарма Боун Дизизис А/С Rtn prodrugs
US11371045B2 (en) 2016-04-15 2022-06-28 Noxxon Pharma Ag Method of modulating the number and the distribution of tumor-infiltrating leukocytes in tumors
AU2017258642B2 (en) 2016-04-29 2023-08-31 Sarepta Therapeutics, Inc. Oligonucleotide analogues targeting human LMNA
CA3030376A1 (en) 2016-07-13 2018-01-18 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
EP3518982A1 (en) 2016-09-29 2019-08-07 Ascendis Pharma Bone Diseases A/S Incremental dose finding in controlled-release pth compounds
EP4275677A3 (en) 2016-09-29 2024-01-10 Ascendis Pharma Bone Diseases A/S Dosage regimen for a controlled-release pth compound
JP7085535B2 (en) 2016-09-29 2022-06-16 アセンディス ファーマ ボーン ディジージズ エー／エス PTH compounds with a small peak-to-trough ratio
KR20230066147A (en) 2016-09-29 2023-05-12 아센디스 파마 그로우쓰 디스오더스 에이/에스 Combination therapy with controlled-release cnp agonists
CN110891611B (en) 2017-03-22 2024-03-29 阿森迪斯制药公司 Hydrogel crosslinked hyaluronic acid prodrug compositions and methods
KR102141124B1 (en) 2018-01-30 2020-08-04 (주)바이오니아 Double-stranded Oligonucleotide Complex comprising Double― stranded miRNA and Uses thereof
CA3093083A1 (en) 2018-03-28 2019-10-03 Ascendis Pharma A/S Conjugates
CA3093722A1 (en) 2018-03-28 2019-10-03 Ascendis Pharma Oncology Division A/S Il-2 conjugates
US20210220387A1 (en) 2018-05-18 2021-07-22 Hoffmann-La Roche, Inc. Pharmaceutical compositions for treatment of microrna related diseases
US20210196801A1 (en) 2018-05-18 2021-07-01 Ascendis Pharma Bone Diseases A/S Starting Dose of PTH Conjugates
WO2020064844A1 (en) 2018-09-26 2020-04-02 Ascendis Pharma A/S Treatment of infections
CN112770781A (en) 2018-09-26 2021-05-07 阿森迪斯药物股份有限公司 Novel hydrogel conjugates
CN113164616A (en) 2018-09-26 2021-07-23 阿森迪斯药物股份有限公司 Degradable hyaluronic acid hydrogel
CN113557033A (en) 2019-01-04 2021-10-26 阿森迪斯药物肿瘤股份有限公司 Conjugates of pattern recognition receptor agonists
EP3906018A1 (en) 2019-01-04 2021-11-10 Ascendis Pharma Oncology Division A/S Induction of sustained local inflammation
MX2021007707A (en) 2019-01-04 2021-08-05 Ascendis Pharma Oncology Div A/S Sustained local drug levels for innate immune agonists.
AU2020205029A1 (en) 2019-01-04 2021-06-24 Ascendis Pharma Oncology Division A/S Minimization of systemic inflammation
SG11202107722VA (en) 2019-02-11 2021-08-30 Ascendis Pharma Bone Diseases As Liquid pharmaceutical formulations of pth conjugates
KR20210130750A (en) 2019-02-11 2021-11-01 아센디스 파마 그로우쓰 디스오더스 에이/에스 Dry Pharmaceutical Formulation of CNP Conjugates
WO2020254613A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
US20220305136A1 (en) 2019-06-21 2022-09-29 Ascendis Pharma Oncology Division A/S Anti-ctla4 conjugates
WO2020254617A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pk properties
EP3986478A1 (en) 2019-06-21 2022-04-27 Ascendis Pharma Oncology Division A/S Tyrosine kinase inhibitor conjugates
WO2020254612A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
WO2020254607A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pd properties
MX2022007371A (en) 2020-01-13 2022-07-12 Ascendis Pharma Bone Diseases As Hypoparathyroidism treatment.
CA3175974A1 (en) 2020-05-04 2021-11-11 Oliver Boris Stauch Hydrogel irradiation
CA3178074A1 (en) 2020-06-03 2021-12-09 Nina Gunnarsson Il-2 sequences and uses thereof
IL300668A (en) 2020-08-28 2023-04-01 Ascendis Pharma Oncology Div A/S Glycosylated il-2 proteins and uses thereof
CN112047840A (en) * 2020-08-31 2020-12-08 山东药品食品职业学院 Synthesis method of 7-bromo-2, 2-dimethylheptanoic acid ethyl ester and product obtained by synthesis
US20230364199A1 (en) 2020-09-28 2023-11-16 Ascendis Pharma Bone Diseases A/S Improvement of physical and mental well-being of patients with hypoparathyroidism
BR112023018802A2 (en) 2021-04-01 2023-10-31 Ascendis Pharma As USE OF LONG-ACTING GROWTH HORMONE FOR THE TREATMENT OF INFLAMMATION-INDUCED DISEASES
KR20240082355A (en) 2021-09-22 2024-06-10 아센디스 파마 본 디지즈 에이/에스 Treatment with long-acting PTH compounds
MX2024006698A (en) 2021-12-13 2024-06-19 Ascendis Pharma Oncology Div A/S Cancer treatments with tlr7/8 agonists.
CA3236278A1 (en) 2021-12-13 2023-06-22 Kennett Sprogoe Effective doses of cnp conjugates
WO2023227505A1 (en) 2022-05-23 2023-11-30 Ascendis Pharma Growth Disorders A/S Liquid pharmaceutical formulations of cnp compounds
WO2023247651A1 (en) 2022-06-21 2023-12-28 TME Pharma AG Methods for treating a tumor in a subject
EP4306640A1 (en) 2022-06-21 2024-01-17 TME Pharma AG Method for treating a tumor in a subject
WO2024094673A1 (en) 2022-11-02 2024-05-10 Ascendis Pharma Bone Diseases A/S Pth treatment regimen comprising two pth compounds
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
WO2024146902A1 (en) 2023-01-05 2024-07-11 Ascendis Pharma A/S Methods of producing hydrogel microspheres
WO2024146920A1 (en) 2023-01-05 2024-07-11 Ascendis Pharma Ophthalmology Division A/S Drug conjugates for the treatment of ocular disorders
WO2024184351A1 (en) 2023-03-06 2024-09-12 Ascendis Pharma A/S Compounds of drugs with an albumin binding moiety
WO2024184354A1 (en) 2023-03-06 2024-09-12 Ascendis Pharma A/S Multi-albumin binding compounds
WO2024184352A1 (en) 2023-03-06 2024-09-12 Ascendis Pharma A/S Drug compounds comprising albumin-binding moieties

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707813A (en) * 1990-05-15 1998-01-13 Diatron Corporation Nucleic acid probes and methods
WO2001013958A2 (en) * 1999-08-26 2001-03-01 Sydney Brenner Drug conjugates and methods of designing the same
US6303569B1 (en) * 1997-12-30 2001-10-16 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6887906B1 (en) * 1997-07-01 2005-05-03 Isispharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904582A (en) * 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
EP1037649B1 (en) * 1997-12-17 2009-09-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
PT1061954E (en) * 1998-03-12 2004-10-29 Nektar Therapeutics Al Corp POLY (ETHYLENE GLYCOL) DERIVATIVES WITH NEXT REACTIVE GROUPS
JP3485023B2 (en) * 1999-05-20 2004-01-13 東亞合成株式会社 Nucleoside compound
KR100406739B1 (en) * 2000-04-15 2003-11-20 주식회사 코오롱 Aqueous-prodrug compound comprising moiety of paclitaxelor derivatives thereof, method of preparing same and pharmaceutical composition comprising same
CA2428018A1 (en) * 2000-12-01 2002-06-06 Enzon, Inc. Tetrapartate prodrugs
US7332164B2 (en) * 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
KR20060015505A (en) * 2003-04-13 2006-02-17 엔존 파마슈티컬즈, 인코포레이티드 Polymeric oligonucleotide prodrugs
CA2662962A1 (en) * 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Polyalkylene oxides having hindered ester-based biodegradable linkers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707813A (en) * 1990-05-15 1998-01-13 Diatron Corporation Nucleic acid probes and methods
US6887906B1 (en) * 1997-07-01 2005-05-03 Isispharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US6303569B1 (en) * 1997-12-30 2001-10-16 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
WO2001013958A2 (en) * 1999-08-26 2001-03-01 Sydney Brenner Drug conjugates and methods of designing the same

Also Published As

Publication number Publication date
JP2010503707A (en) 2010-02-04
KR20090055623A (en) 2009-06-02
AU2007296054B2 (en) 2013-03-28
IL197516A0 (en) 2009-12-24
EP2063709A2 (en) 2009-06-03
AU2007296054A1 (en) 2008-03-20
CN101534643A (en) 2009-09-16
MX2009002859A (en) 2009-03-30
WO2008034122A2 (en) 2008-03-20
CA2662978A1 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
WO2008034122A3 (en) Hindered ester-based biodegradable linkers for oligonucleotide delivery
EP2097464A4 (en) Polyamide polyols and polyurethanes, methods for making and using, and products made therefrom
WO2006020768A3 (en) Chemically modified oligonucleotides
EP1981544A4 (en) Biodegradable and thermosensitive poly(organophosphazene) hydrogel, preparation method thereof and use thereof
WO2008036765A3 (en) Micrornas differentially expressed in pancreatic diseases and uses thereof
IL191147A0 (en) Peptide-dicer substrate rna conjugates as delivery vehicles for sirna
EP2076326A4 (en) Ce-zr-r-o catalysts, articles comprising the ce-zr-r-o catalysts and methods of making and using the ce-zr-r-o catalysts
WO2007121131A3 (en) Medical devices including shape memory materials
WO2007136969A3 (en) Bioabsorbable magnesium-reinforced polymer stents
EP1942831A4 (en) Twist-down implant delivery technologies
EP1991688A4 (en) Biodegradable compositions comprising renewably-based, biodegradable 1.3-propanediol
GB0402131D0 (en) Delivery method
WO2008034007A3 (en) Medical devices
EP1915449A4 (en) Sirna-hydrophilic polymer conjugates for intracellular delivery of sirna and method thereof
IL206395A (en) N-heterocyclyl-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-2-carboxamides and pharmaceutical compositions comprising them
IL179973A0 (en) Immunostimulatory oligonucleotide multimers
WO2007121318A3 (en) Formulations for delivering insulin
HK1112427A1 (en) Drug delivery compositions and related methods
WO2007095316A3 (en) Compositions and methods for oligonucleotide formulations
WO2007103666A3 (en) Implantable medical endoprosthesis delivery systems
EP1723162A4 (en) Anti-microrna oligonucleotide molecules
EP2158254A4 (en) Poly(organophosphazene) hydrogels for drug delivery, preparation method thereof and use thereof
IL198911A0 (en) Drug delivery
WO2007143086A3 (en) Delivery method
WO2008033300A8 (en) Bis (thiohydrazide amides) formulation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780041936.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07842576

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 435/MUMNP/2009

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2662978

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/002859

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2009528517

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007296054

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007842576

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020097007157

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2007296054

Country of ref document: AU

Date of ref document: 20070915

Kind code of ref document: A